ALEXANDRIA, Va., Feb. 3 -- United States Patent no. 12,540,127, issued on Feb. 3, was assigned to Kymera Therapeutics Inc. (Watertown, Mass.).
"CRBN ligands and uses thereof" was invented by Nello Mainolfi (Belmont, Mass.), Nan Ji (Arlington, Mass.), Yi Zhang (Belmont, Mass.) and Matthew M. Weiss (Boston).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders."
The patent was filed on May 11, 2022, under Application No. 17/741,890.
*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Se...